ES2096035T3 - Compuestos y procedimientos para el tratamiento de trastornos tromboembolicos. - Google Patents

Compuestos y procedimientos para el tratamiento de trastornos tromboembolicos.

Info

Publication number
ES2096035T3
ES2096035T3 ES92305336T ES92305336T ES2096035T3 ES 2096035 T3 ES2096035 T3 ES 2096035T3 ES 92305336 T ES92305336 T ES 92305336T ES 92305336 T ES92305336 T ES 92305336T ES 2096035 T3 ES2096035 T3 ES 2096035T3
Authority
ES
Spain
Prior art keywords
treatment
thromboembolic disorders
procedures
compounds
adducts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305336T
Other languages
English (en)
Inventor
Philip John Burck
Ronald Eugene Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2096035T3 publication Critical patent/ES2096035T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SUMINISTRA ABDUCTORES DE DERIVADOS DEL T-PA HUMANO, DICHOS ABDUCTORES COMPRENDEN UN DERIVADO DEL T-PA QUE CARECE DE LAS ZONAS DEL FACTOR DE CRECIMIENTO Y "KRINGLE 1", UNIDO A UNA MOLECULA ANFIPATICA. LA INVENCION TAMBIEN SUMINISTRA METODOS PARA PREPARAR DICHOS ABDUCTORES Y COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES TROMBOEMBOLICAS.
ES92305336T 1991-06-13 1992-06-11 Compuestos y procedimientos para el tratamiento de trastornos tromboembolicos. Expired - Lifetime ES2096035T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/714,537 US5272076A (en) 1991-06-13 1991-06-13 Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA

Publications (1)

Publication Number Publication Date
ES2096035T3 true ES2096035T3 (es) 1997-03-01

Family

ID=24870421

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305336T Expired - Lifetime ES2096035T3 (es) 1991-06-13 1992-06-11 Compuestos y procedimientos para el tratamiento de trastornos tromboembolicos.

Country Status (9)

Country Link
US (1) US5272076A (es)
EP (1) EP0518652B1 (es)
JP (1) JPH05184365A (es)
AT (1) ATE147409T1 (es)
CA (1) CA2071145A1 (es)
DE (1) DE69216479T2 (es)
DK (1) DK0518652T3 (es)
ES (1) ES2096035T3 (es)
GR (1) GR3022779T3 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
EP0293934B1 (en) * 1987-06-04 1994-08-31 Zymogenetics, Inc. Mutant t-PA with kringle replacement
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤

Also Published As

Publication number Publication date
JPH05184365A (ja) 1993-07-27
EP0518652B1 (en) 1997-01-08
US5272076A (en) 1993-12-21
ATE147409T1 (de) 1997-01-15
DK0518652T3 (da) 1997-06-30
DE69216479D1 (de) 1997-02-20
EP0518652A1 (en) 1992-12-16
DE69216479T2 (de) 1997-05-15
GR3022779T3 (en) 1997-06-30
CA2071145A1 (en) 1992-12-14

Similar Documents

Publication Publication Date Title
HUT64310A (en) Compositions containing substituted aryl-halogenalkyl-pyrazol derivatives having herbicidal activity and process for producing said compounds
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
EP0328251A3 (en) 2-(2-hydroxy-3-phenoxypropylamino)ethylphenoxyacetamides and processes and intermediates for their preparation
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
DK217588A (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
GR3015817T3 (en) Substituted alpha-amino acids having pharmaceutical activity.
IL111580A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ZA878249B (en) Method and therapeutic compositions for the treatment of bleeding disorders
BR8907445A (pt) Eteres de oxabicicloalcano herbicidas
ES2096035T3 (es) Compuestos y procedimientos para el tratamiento de trastornos tromboembolicos.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
EP0416810A3 (en) Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates
IL89901A (en) Strobilurine derivative
EP0429324A3 (en) Use of n-methyl-2-(3-pyridyl)2-tetrahydrothiopyran-carbothioamide-1-oxide for the preparation of medicaments for the treatment of coronary insufficiency
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518652

Country of ref document: ES